Cosmos Health Inc. (COSM) company profile
Close on Nov 17, 2026Market cap $286.81MP/E –Yield –
About Cosmos Health
Wholesale-Drugs, Proprietaries & Druggists' Sundries, SIC 5122
Cosmos Health Inc. is a vertically integrated healthcare company that develops, manufactures, and distributes generic pharmaceuticals, proprietary nutraceuticals, biocides, and other healthcare products. The company also operates a direct-to-consumer telehealth platform and conducts research and development focused on novel oncology therapies, weight management solutions, and AI-driven drug repurposing. Its offerings encompass prescription and over-the-counter medications, antiseptic soaps, and dietary supplements, as well as contract manufacturing organization services. The group's customer base includes retail pharmacies, wholesale drug distributors, hospitals, and clinics, along with individual consumers using its virtual care services.
The company's commercial activities are primarily concentrated in Europe, with Greece generating the vast majority of consolidated revenues alongside operations in the United Kingdom, other European countries, and the United Arab Emirates, with expansion into North America. Operations are supported by automated storage and distribution facilities utilizing robotic warehouse systems. The enterprise was originally incorporated in Nevada.
Summary of the business section of Cosmos Health's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Cosmos Health Inc.
- Founded
- 2009
- Headquarters
- Thessaloniki, J3
- Address
- 5 Agiou Georgiou, Pilea 55438
- Phone
- (312) 536-3102
- Website
- cosmoshealthinc.com
- Employees
- 163, Dec 31, 2025
- Industry
- Wholesale-Drugs, Proprietaries & Druggists' Sundries
- Incorporated in
- Nevada
- Fiscal year ends
- December 31
- Auditor
- RBSM LLP, New York, NY
Stock & identifiers
- Ticker
- COSM
- Former tickers
- PMLT until Aug 16, 2021
- Exchange
- Nasdaq
- IPO date
- Jul 23, 2010
- Shares outstanding
- 101M, Aug 18, 2026
- Public float
- $9.53M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-25 reverse, Apr 12, 2023; 1-for-10 reverse, Apr 17, 2018; 1-for-10 reverse, Nov 21, 2017
- SEC CIK
- 1474167
- CUSIP
- 221413305
- ISIN
- US2214133058
- FIGI
- BBG000QXZGP7
- Share class FIGI
- BBG001T8QZQ4
- LEI
- 549300NN5KFIEHPECJ85
- EIN
- 27-0611758
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Grigorios Siokas | Chief Executive Officer, Director | 14,597,917 |
| Demetrios G. Demetriades | Secretary, Director | 55,000 |
| Georgios Terzis | Chief Financial Officer | 2,563,805 |
| Nikolaos Bardakis | Chief Operating Officer | 45,000 |
| Anastasios Aslidis | Director | 100,000 |
| Suhel Bhutawala | Director | 65,000 |
| John James Hoidas | Director | 50,000 |
| Theodoros Christos Karkantzos | Director | 35,000 |
| Manfred Ziegler | Director | 20,000 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Grigorios Siokas | $1.08M | $1.80M | $672.30K | – | $3.55M | +22% |
| Georgios Terzis | $148.24K | $200.00K | $244.02K | – | $592.26K | -22% |
| Nikolaos Bardakis | $23.95K | – | – | $15.43K | $39.38K | -55% |
| Suhel Bhutawala | $66.41K | – | $7.47K | $10.00K | $83.88K | -30% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had a total of 163 full-time employees.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?